RD antigen based nanovaccine imparts long term protection by inducing memory response against experimental murine tuberculosis

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Ansari, Mairaj Ahmed ^a   Zubair, Swaleha ^a   Mahmood, Anjum ^b   Gupta, Pushpa ^c   Khan, Aijaz A ^d   Gupta, Umesh D ^c   Arora, Ashish ^b   Owais, Mohammad ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c National JALMA Institute for Leprosy and OMD   (India)

^d ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARCHEOSOME; CYTOKINE; IMMUNOLOGICAL ADJUVANT; MYCOBACTERIUM VACCINE; NANOVACCINE; RD ANTIGEN; RV3619C PROTEIN; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BCG VACCINE; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; NANOPARTICLE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL MURINE TUBERCULOSIS; FEMALE; IMMUNE RESPONSE; MEMORY T LYMPHOCYTE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CYTOLOGY; FLOW CYTOMETRY; HUMAN; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LUNG; METABOLISM; MICROBIOLOGY; PATHOLOGY; TH1 CELL; TIME;

ANIMALIA; MURINAE; MUS; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; BIOLOGICAL MARKERS; CELL PROLIFERATION; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; TH1 CELLS; TIME FACTORS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 80051644799     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022889     Document Type: Article

References (35)

1. World Health Organization (2009) Epidemiology. pp. 6-33 Global tuberculosis control: epidemiology, strategy, financing.
2. Maartens G, Wilkinson RJ, (2007) Tuberculosis. Lancet 370: 2030-2043.
3. World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO Geneva, (WHO/HTM/TB/2010.3).
4. Nelson LJ, Talbot EA, Mwasekaga MJ, Nghirubiu PK, Mwansa RA, et al. (2005) Antituberculosis drug resistance anonymous HIV surveillance in tuberculosis patients in Botswana, 2002. Lancet 366: 488-490.
5. Nunes EA, De Capitani EM, Coelho E, Joaquim OA, Figueiredo RO, et al. (2005) Patterns of anti-tuberculosis drug resistance among HIV-infected patients in Maputo, Mozambique, 2002-2003. Int J Tuber Lung Dis 9: 494-500.
6. Petroff SA, Branch A, (1928) Bacillus Calmette-Gue' rin (BCG) Animal experimentation and prophylactic immunization of children. Am J Public Health 18: 843-864.
7. Andersen P, Doherty TM, (2005) The success and failure of BCG: implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-662.
8. Doherty TM, Andersen P, (2005) Vaccines for tuberculosis: novel concepts and recent progress. Clin Microbiol Rev 18: 687-702.
9. Mahmood A, Srivastava S, Tripathi S, Ansari MA, Owais M, et al. (2011) Molecular characterization of secretory proteins from RD9 region of Mycobacterium tuberculosis H37Rv. FEBS Journal 278: 341-353.
10. Elvang T, Christensen JP, Billeskov R, Thi Kim Thanh Hoang T, Holst P, et al. (2009) CD4 and CD8 T Cell Responses to the M. tuberculosis Ag85B-TB10.4 Promoted by Adjuvanted Subunit, Adenovector or Heterologous Prime Boost Vaccination. PLoS ONE 4: e5139.
11. Van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P, (2000) Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 30: 3689-3698.
12. Sjolander A, Cox JC, Barr IG, (1998) ISCOMs: an adjuvant with multiple functions. J Leukocyte Biol 64: 713-723.
13. Simmons CP, Mastroeni P, Fowler R, Ghaem-Maghami M, Lycke N, et al. (1999) MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol 163: 6502-6510.
14. Gupta RK, Rost BE, Reyveld E, Siber GS, (1995) Adjuvant properties of aluminum and calcium compounds. In: Powell MF, Newman MJ, editors. Vaccine Design: The Subunit and Adjuvant Approach Plenum, New York.
15. Sprott GD, Dicaire CJ, Fleming LP, Patel GB, (1996) Stability of liposomes prepared from archaeobacterial lipids and phosphatidylcholine mixtures. Cells Mat 6: 143-155.
16. Choquet CG, Patel GB, Sprott GD, (1996) Heat sterilization of archaeal liposomes. Can J Microbiol 42: 183-186.
17. Mathai JC, Sprott GD, Zeidel ML, (2001) Molecular Mechanism of water and Solute Transport across Archaebacterial Lipid Membranes. J Biol Chem 276: 27266-27271.
18. Krishnan L, Dicaire CJ, Patel GB, Sprott GD, (2000) Archaeosome vaccine adjuvants induce strong humoral, cell-mediated and memory responses: comparison to conventional liposomes and alum. Infect Immun 68: 54-63.
19. Sprott GD, Tolson DL, Patel GB, (1997) Archaeosomes as novel antigen delivery systems. FEMS Microbiol Lett 154: 17-22.
20. Krishnan L, Sad S, Patel GB, Sprott GD, (2000) Archaeosomes induce long-term CD81 cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway in the absence of CD4+ T cell help. J Immunol 165: 5177-5185.
21. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P, (2000) ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68: 791-795.
22. Grover A, Ahmed MF, Verma I, Sharma P, Khuller GK, (2006) Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model, Protein Expression Purif 48: 274-280.
23. Sable SB, Verma I, Behera D, Khuller GK, (2005) Human immune recognition-based multicomponent subunit vaccines against tuberculosis. Eur Respir J 25: 902-910.
24. Zhang M, Gong J, Lin Y, Barnes PF, (1998) Growth of virulent and virulent Mycobacterium tuberculosis strains in human macrophages. Infect Immun 66: 794-799.
25. Sambrook J, Russel DW, (2001) Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor, NY.
26. Kumar A, Gupta CM, (1983) Red cell membrane abnormalities in chronic myeloid leukaemia. Nature 303: 632-633.
27. Kirby C, Gregoriadis G, (1984) Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 2: 979-984.
28. Mallick AI, Singha H, Khan S, Anwar T, Ansari MA, et al. (2007) Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. Vaccine 25: 7873-7884.
29. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
30. Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, et al. (2008) Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis. J Immunol 181: 7948-7957.
31. Lenschow DJ, Walunas TL, Bluestone JA, (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258.
32. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, et al. (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4: 225-234.
33. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, et al. (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8: 379-385.
34. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, et al. (2001) Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410: 106-111.
35. Gareth JJ, Stephen VG, Hewinson RG, Vordermeier HM, (2010) Screning of predicted Secreted Antigens from Mycobacterium bovis reveals the Immunodominance of the ESAT-6 Protein Family. Infect Immun 78: 1326-1332.